Navigation Links
Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
Date:11/30/2007

ns in blood pressure than either drug alone. This, along with its favorable side-effect profile, should make AZOR an attractive treatment option for patients whose blood pressure does not respond to either component drug in isolation. U.S. approval was granted in September 2007.

While the reason for menopause remains unknown, KV Pharmaceutical believes EvaMist, which takes the third spot on the list, may offer significant advantages to women experiencing menopause. This product is a small, easy-to- use hand-held applicator that delivers a pre-set metered dose via the skin, releasing estradoil into the bloodstream over 24 hours. EvaMist gained FDA approval in July 2007.

The first of two potential treatments for cancer on the list of notable drugs gaining approval this quarter is Yondelis, developed by PharmaMar for patients who have not responded to previous regimens in their treatment of soft tissue sarcoma. Yondelis is the first approved product from PharmaMar, a Spanish biotech specializing in cancer drugs derived from marine organisms and has Orphan Drug status in both the EU and U.S., securing extended protection against generic competition.

The second approval win for Novartis this quarter, Tasigna, is an orally available inhibitor of Bcr-Abl, c-Kit, PDGF-R and related receptor tyrosine kinases for the potential treatment of various types of leukemia. Though the drug has been approved only in Switzerland for chronic myeloid leukemia, it is awaiting approval in the U.S. and Japan and has been recommended for approval across the EU.

Following are the top five drugs in each category of phase changes:

The Five Most Promising Drugs Entering Phase III Trials

* bevasiranib sodium, (Wet AMD), Opko

* recombinant active glucocerebrosidase, (Gaucher's disease), Protalix

* odanacatib, (osteoporosis), Merck & Co

* laquinimod, (multiple sclerosis), Active Biotech/Teva

* elesclomol, (solid tumors), Synta
'/>"/>

SOURCE Thomson Scientific
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Thomson Scientific Predicts Nobel Laureates
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
6. Thomson Acquires Prous Science
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. Thomson Scientific Ranks Australian Universities and Research Institutes
9. Thomson Healthcare Study Finds That Hospitals Delivering High-Quality Heart Care Are Efficient and Cost Effective, Too
10. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
11. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... NY (PRWEB) , ... July 07, 2015 , ... ... email newsletter and website that helps active people find the most fun activities to ... active lifestyle coverage for millennials. It also increases Greatist’s opportunity for events, e-commerce, and ...
(Date:7/7/2015)... , ... July 07, 2015 , ... Quadrino Law Group ... Road, Suite 304, Melville, New York 11747. The new facility is a state ... and rail lines. , Richard Quadrino, the firm's CEO and founder, said, "We are ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... SC&H Group, ... Service, which aims to give back to the community through company-wide volunteering efforts. , ... SC&H Group dedicate the day to assisting those in need throughout Baltimore and Washington ...
(Date:7/7/2015)... ... , ... At the end of June Pacific Prime Renewals team in Hong Kong announced ... by the Renewals Manager, Danielle Cotton, aims to not only reduce but eventually eliminate the ... explained, “We send anything between 300 and 600 pieces of paper per month. Not to ...
(Date:7/7/2015)... ... ... Summer is a great time to get outside and be active. It’s ... tips. , Jean Tapley, senior wellness coordinator at Amica, suggests the following seven tips ... Start slowly. Going from no activity to several hours of activity can potentially be ...
Breaking Medicine News(10 mins):Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Amica Insurance Has 7 Summer Safety Tips 2
... emergency department with complaints that may signal a sexually ... be tested than blacks, according to a study to ... Societies (PAS) annual meeting in Denver. Researchers, ... that pediatric emergency medicine physicians are less likely to ...
... surgery has become a mainstream tool for removing an ever-increasing ... head and neck surgeons from Mayo Clinic has found robotic ... the tongue at the top of the voice box. ... or radiation, and most could resume normal eating and speaking. ...
... MD, DSc, Professor of Medicine at Harvard Medical School ... Solomon A. Berson Distinguished Lectureship at the annual meeting ... (FASEB) held earlier this month in Washington, DC. ... development of the methodologies for radioimmunoassay led to discoveries ...
... -- Breast cancer patients with low levels of vitamin D ... finds. Experts say the new findings support what many ... vitamin D is related to breast health in some way, ... Kirstein, a breast surgeon at Beth Israel Medical Center in ...
... Md. (April 27, 2011)A U.S. senator, an Army leader and ... to be honored May 4 by the Henry M. Jackson ... Partnerships. The awards dinner, which will take place ... Washington, D.C., will recognize outstanding contributions by service members, veterans ...
... and CEO of the Regenstrief Institute and associate dean ... of Medicine, received a 2011 Distinguished Investigator Award presented ... on April 28 in Washington, DC. Dr. Tierney ... to Clinical and Translational Science. He is being honored ...
Cached Medicine News:Health News:Race a factor in whether young women are tested for sexually transmitted infections 2Health News:Mayo Clinic finds robotic surgery effective for removing hard-to-reach throat cancer 2Health News:Christos Mantzoros honored by Federation of the American Societies for Experimental Biology 2Health News:Low Vitamin D Levels Linked to More Aggressive Breast Cancers 2Health News:Low Vitamin D Levels Linked to More Aggressive Breast Cancers 3Health News:Dinner to honor icons of military medicine 2Health News:Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2
(Date:7/7/2015)... Calif. , July 7, 2015  Essentialis, a venture-backed ... agonists for the treatment of orphan neurobehavioral and metabolic diseases, ... and CSO, will present a corporate update at the Cantor ... Conference Date: Wednesday, July 8, 2015 Time: ... About Essentialis, Inc. ...
(Date:7/7/2015)... NEW YORK , July 7, 2015 ... new generation of drugs within human and veterinary oncology, ... the Securities and Exchange Commission, in connection with the ... the NASDAQ Stock Market. The number of American Depositary ... price range for the offering have not yet been ...
(Date:7/7/2015)... Ill. , July 7, 2015  Monopar Therapeutics ... oncology compounds, announced that its co-founder and CEO, ... British Council,s Education U.K. Alumni Entrepreneurial Award. The British ... China , India , and ... recognizes outstanding achievements made by entrepreneurs who have leveraged ...
Breaking Medicine Technology:Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3
... 2011 Scientists at Osel Inc . and ... a new way to prevent HIV infection by genetically ... block viral transmission. Bioengineered bacteria introduced into the vaginal ... of simian HIV (SHIV) by nearly two thirds. ...
... July 18, 2011 Data from high-risk patients requiring ... nondeferrable, non-cardiac surgery show good short- and long-term clinical ... according to a study published online on the journal ... In the single-center study, patients treated with the Genous ...
Cached Medicine Technology:Scientists Use Live Bacteria to Fight HIV 2Scientists Use Live Bacteria to Fight HIV 3OrbusNeich's Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery 2OrbusNeich's Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery 3
The Lang Stereotest was created to simplify stereopsis screening in children. It is based on two principles: random dots and cylindrical gratings. The Lang Stereotest I measures disparities: Star 600...
Comes with seven test plates. Red and green glasses filters are mounted in two frames, one for adults and one for children. Suitable for testing very small children as well as adults....
Last 3-6 months average refrigeration will prolong life. Pupil gauge printed on penlight 4 1/2" long 1/2" around....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
Medicine Products: